Cancer drug developer Celldex Therapeutics Inc. said on Saturday that one of its drugs extended survival in a trial of 65 brain cancer patients.
The company's injectable CDX-110 is designed to treat glioblastoma, the most common and aggressive type of brain cancer.
It said the most recent study showed that two-thirds of patients' cancer had not progressed 8.5 months after diagnosis, which was 5.5 months after they got the drug. It said the result was better than those for patients who receive the usual treatment of radiation plus temozolomide, and was consistent with two other studies. The company plans a larger, clinical trial in the second half of next year.
The drug is designed to stimulate the immune system to fight cancer. It targets a growth factor found only in cancer cells.